Abstract
In cancer, increased levels of the tumor-associated serine protease uPA (urokinase-type plasminogen activator) and its receptor uPAR (CD87) are linked to tumor progression, metastasis, and shortened survival in patients afflicted with this disease. Strong clinical and experimental evidence has accumulated that the cell surface interaction of uPA with uPAR facilitates extravasation and intravasation of cancer cells by regulating local proteolysis and attachment of the cells to components of the extracellular matrix. Moreover, the uPA / uPAR system is also implicated in proliferation of some tumor cells and migration of tumor and endothelial cells. Thus, metastasis formation is facilitated via tumor cell spread through the blood circulation system and neovascularization at the metastatic site. This multifunctional potential has rendered the uPA / uPAR system an attractive novel target for anti-metastatic therapy. Consequently, inhibitors of the uPA / uPAR interaction have been and are currently developed for suppression of tumor growth and angiogenesis. In addition to antibodies and recombinant uPA- or uPAR-derived proteins, various linear and cyclic peptides as well as small molecules have been designed and synthesized which potently interfere with the uPA / uPAR interaction, leading to reduced tumor progression in experimental animals. Such compounds affecting the uPA / uPAR system represent novel tumor biology-based therapeutic agents, thereby opening new ways for patient optimized and individualized cancer therapy.
Keywords: urokinase, urokinase receptor, tumor invasion, cancer therapy, d-amino acid, antagonists
Current Pharmaceutical Design
Title: Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo
Volume: 9 Issue: 19
Author(s): Ute Reuning, Stefan Sperl, Charlotte Kopitz, Horst Kessler, Achim Kruger, Manfred Schmitt and Viktor Magdolen
Affiliation:
Keywords: urokinase, urokinase receptor, tumor invasion, cancer therapy, d-amino acid, antagonists
Abstract: In cancer, increased levels of the tumor-associated serine protease uPA (urokinase-type plasminogen activator) and its receptor uPAR (CD87) are linked to tumor progression, metastasis, and shortened survival in patients afflicted with this disease. Strong clinical and experimental evidence has accumulated that the cell surface interaction of uPA with uPAR facilitates extravasation and intravasation of cancer cells by regulating local proteolysis and attachment of the cells to components of the extracellular matrix. Moreover, the uPA / uPAR system is also implicated in proliferation of some tumor cells and migration of tumor and endothelial cells. Thus, metastasis formation is facilitated via tumor cell spread through the blood circulation system and neovascularization at the metastatic site. This multifunctional potential has rendered the uPA / uPAR system an attractive novel target for anti-metastatic therapy. Consequently, inhibitors of the uPA / uPAR interaction have been and are currently developed for suppression of tumor growth and angiogenesis. In addition to antibodies and recombinant uPA- or uPAR-derived proteins, various linear and cyclic peptides as well as small molecules have been designed and synthesized which potently interfere with the uPA / uPAR interaction, leading to reduced tumor progression in experimental animals. Such compounds affecting the uPA / uPAR system represent novel tumor biology-based therapeutic agents, thereby opening new ways for patient optimized and individualized cancer therapy.
Export Options
About this article
Cite this article as:
Reuning Ute, Sperl Stefan, Kopitz Charlotte, Kessler Horst, Kruger Achim, Schmitt Manfred and Magdolen Viktor, Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo, Current Pharmaceutical Design 2003; 9 (19) . https://dx.doi.org/10.2174/1381612033454612
DOI https://dx.doi.org/10.2174/1381612033454612 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An overview of ABC and SLC Drug Transporter Gene Regulation
Current Drug Metabolism miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Genetic Alterations in Differentiated Thyroid Cancers
Endocrine, Metabolic & Immune Disorders - Drug Targets A Novel Approach to Anticancer Therapies: Peroxisome Proliferator Activator-Receptor-γ as a New Target Therapy in the Treatment of Human Urological Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Cubilin, the Intrinsic Factor-Vitamin B12 Receptor in Development and Disease
Current Medicinal Chemistry Overview of Mechanisms of Cancer Stem Cell Drug Resistance
Current Signal Transduction Therapy Progesterone Receptor Agonists and Antagonists as Anticancer Agents
Mini-Reviews in Medicinal Chemistry The Impact of Gynecological Cancer on Reproductive Issues and Pregnancy:Psychological Implications
Current Women`s Health Reviews Trophoblast Invasion: A Possible Link Between Implantation Deficiencies and Preeclampsia
Current Women`s Health Reviews Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology Preface
Current Molecular Medicine Oncogenic Signaling Pathways Activated by RON Receptor Tyrosine Kinase
Current Cancer Drug Targets Effects of Limonoid Cedrelone on MDA-MB-231 Breast Tumor Cells in vitro
Anti-Cancer Agents in Medicinal Chemistry Prospects of Molecularly-Targeted Therapies for Cervical Cancer Treatment
Current Drug Targets Molecular Basis of Gestational Trophoblastic Diseases
Current Molecular Medicine Drug Transport Across the Placenta
Current Pharmaceutical Biotechnology Glycine Transporter Type-1 and its Inhibitors
Current Medicinal Chemistry Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry The Effects of Insulin and Insulin-Like Growth Factors on Tumor Vascularization: New Insights of Insulin-Like Growth Factor Family in Cancer
Current Medicinal Chemistry Engagement of Renin-Angiotensin System in Prostate Cancer
Current Cancer Drug Targets